CAR-T Cell Therapy vs Stem Cell Transplant — Clinical Trial Comparison
CAR-T Cell Therapy
Engineered T-cells targeting specific cancer antigens
VS
Stem Cell Transplant
Replace diseased bone marrow with healthy stem cells
CAR-T cell therapy and stem cell transplant are two of the most advanced treatments for blood cancers, and both are areas of intense clinical research in the UK. While stem cell transplantation has been a curative approach for decades, CAR-T represents a revolutionary form of personalised immunotherapy. Many patients facing relapsed or refractory blood cancers will encounter both options — understanding the trial landscape can help guide your decisions.
Key Differences at a Glance
| Feature | CAR-T Cell Therapy | Stem Cell Transplant |
|---|---|---|
| Mechanism | Patient's T-cells are genetically engineered to express chimeric antigen receptors (CARs) that recognise cancer cells | Healthy stem cells (from patient or donor) replace diseased bone marrow after high-dose chemotherapy/radiation |
| Autologous vs allogeneic | Currently only autologous (patient's own T-cells) approved; allogeneic CAR-T in trials | Both autologous (self) and allogeneic (donor) transplants are standard |
| Treatment process | Leukapheresis → manufacturing (2–4 weeks) → lymphodepletion → CAR-T infusion | Stem cell harvest → conditioning chemotherapy → stem cell infusion → engraftment |
| Typical cancers treated | DLBCL, ALL, mantle cell lymphoma, follicular lymphoma, multiple myeloma | AML, ALL, lymphoma, myeloma, MDS, CML, aplastic anaemia |
| Hospital stay | Usually 2–4 weeks for monitoring (cytokine release syndrome risk) | 4–8 weeks for allogeneic; shorter for autologous |
| Long-term risks | B-cell aplasia, hypogammaglobulinaemia, secondary malignancies (rare) | Graft-vs-host disease (allogeneic), infections, organ toxicity, secondary malignancies |
Clinical Trial Availability
| Trial Aspect | CAR-T Cell Therapy | Stem Cell Transplant |
|---|---|---|
| UK trials actively recruiting | 30–60 studies | 50–80 studies |
| Most common phases | Phase 1–2 (rapidly expanding to Phase 3) | Phase 2–3 |
| Top conditions studied | DLBCL, ALL, multiple myeloma, mantle cell lymphoma, follicular lymphoma | AML, myelodysplastic syndromes, ALL, lymphoma, myeloma, aplastic anaemia |
| Novel approaches in trials | Dual-target CAR-T, allogeneic "off-the-shelf" CAR-T, CAR-NK, logic-gated CARs | Haploidentical transplants, reduced-intensity conditioning, post-transplant maintenance, cord blood |
| Combination trials | CAR-T + checkpoint inhibitors, CAR-T + bispecific antibodies | Transplant + maintenance therapy, transplant + targeted therapy |
| Age focus | Expanding from paediatric/young adult to older patients | Both paediatric and adult; age limits vary by protocol |
Exciting Emerging Treatments
CAR-T Cell Therapy Trials
- Allogeneic CAR-T (off-the-shelf) — donor T-cells for faster, cheaper treatment
- Dual-target CAR-T — targeting CD19 + CD22 or BCMA + GPRC5D
- CAR-NK cell therapy — natural killer cells with CAR constructs
- Logic-gated CAR-T — "AND/OR/NOT" circuits for tumour specificity
- Earlier-line use — moving CAR-T from 3rd/4th line to 2nd line and beyond
- In vivo CAR-T — engineering T-cells inside the body using viral vectors
Stem Cell Transplant Trials
- Haploidentical transplants — half-matched donors expanding access dramatically
- Reduced-intensity conditioning — making transplant available for older patients
- Post-transplant maintenance — targeted therapies to prevent relapse
- Cord blood transplant optimisation — ex vivo expansion of cord blood units
- Post-transplant immunotherapy — preventing relapse with checkpoint inhibitors
- Microbiome-guided approaches — gut flora optimisation for better outcomes
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
CAR-T Cell Therapy Trial Criteria
- Confirmed diagnosis of target condition (e.g., CD19+ B-cell lymphoma, BCMA+ myeloma)
- Relapsed or refractory disease after standard therapies
- Adequate organ function (cardiac, renal, hepatic, pulmonary)
- ECOG performance status 0–1 (some allow 0–2)
- No active uncontrolled infection
- Sufficient T-cell function for leukapheresis
Stem Cell Transplant Trial Criteria
- Confirmed haematological diagnosis requiring transplant
- Adequate organ function for conditioning regimen
- Donor availability (matched related, matched unrelated, or haploidentical for allogeneic)
- Disease in appropriate state (remission, partial response, or stable disease)
- No active uncontrolled infection
- Age and comorbidity assessment (HCT-CI score)
CAR-T Cell Therapy Trials
Find actively recruiting CAR-T clinical trials across the UK
CAR-T Cell Therapy TrialsStem Cell Transplant Trials
Find actively recruiting stem cell transplant trials across the UK
Stem Cell Transplant TrialsFrequently Asked Questions
Can I have CAR-T after a stem cell transplant?
Yes — CAR-T is increasingly used as salvage therapy after transplant relapse. In fact, many CAR-T trials specifically enrol patients who have relapsed after autologous or allogeneic stem cell transplant. Your haematologist can advise on sequencing.
Is CAR-T replacing stem cell transplant?
Not entirely. CAR-T is expanding into earlier lines of therapy, but stem cell transplant remains the standard curative approach for many blood cancers, particularly AML and MDS. They are complementary rather than competing approaches, and combination strategies are being actively studied.
Which treatment has a faster recovery?
CAR-T typically has a shorter hospital stay (2–4 weeks) compared to allogeneic transplant (4–8 weeks), but recovery is highly individual. CAR-T recovery focuses on managing cytokine release syndrome and neurological side effects, while transplant recovery centres on engraftment and preventing graft-versus-host disease.